Cboe AU - Delayed Quote AUD

BPH Global Ltd (BP8.XA)

Compare
0.0030 0.0000 (0.00%)
At close: September 30 at 10:55 AM GMT+10
Loading Chart for BP8.XA
DELL
  • Previous Close 0.0030
  • Open 0.0000
  • Bid --
  • Ask 0.0040 x --
  • Day's Range 0.0030 - 0.0030
  • 52 Week Range 0.0020 - 0.0100
  • Volume 0
  • Avg. Volume 247,250
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 1.03
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Aug 30, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

BPH Global Ltd, together with its subsidiaries, engages in sourcing, producing, marketing, and selling traditional medicines in Australia, Singapore, China, and Malaysia. Its products include Caulerpa Lentillifera, a sea grape extract; Dendrobium Officinale Kimura et Migo, an orchid; Resina, a Daemonorops Draco Blume extract; and Cannabis Sativa, an industrial hemp. The company was formerly known as Stemcell United Limited and changed its name to BPH Global Ltd in June 2023. BPH Global Ltd was incorporated in 1984 and is headquartered in Melbourne, Australia.

www.scu.com.sg

--

Full Time Employees

June 30

Fiscal Year Ends

--

Sector

--

Industry

Recent News: BP8.XA

View More

Performance Overview: BP8.XA

Trailing total returns as of 10/1/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BP8.XA
0.00%
MSCI WORLD
17.44%

1-Year Return

BP8.XA
0.00%
MSCI WORLD
30.45%

3-Year Return

BP8.XA
0.00%
MSCI WORLD
23.79%

5-Year Return

BP8.XA
96.00%
MSCI WORLD
70.73%

Compare To: BP8.XA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BP8.XA

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -99.30%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    109.97k

  • Net Income Avi to Common (ttm)

    -1.6M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    134.82k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -935.87k

Research Analysis: BP8.XA

View More

Company Insights: BP8.XA

Research Reports: BP8.XA

View More